Connect
MJA
MJA

Drug treatment for melanoma: progress, but who pays?

Sonia Fullerton
Med J Aust 2012; 197 (9) || doi: 10.5694/mja12.11249
Published online: 5 November 2012

To the Editor: Kefford’s contention that making cancer drugs affordable requires coherent policy and cannot be left to market forces1 is correct.

The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.


  • Eastern Health, Melbourne, VIC.



Competing interests:

No relevant disclosures.

  • 1. Kefford RF. Drug treatment for melanoma: progress, but who pays? Med J Aust 2012; 197: 198-199. <MJA full text>
  • 2. Pronovost PJ, et al. How can clinicians measure safety and quality in acute care? Lancet 2004; 363: 1061-1067.
  • 3. Bruera E, Yennurajalingam S. Palliative care in advanced cancer patients: how and when? Oncologist 2012; 17: 267-73.
  • 4. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
  • 5. Palliative Care Australia. National Palliative Care Consensus Statement: a call to action. Canberra: PCA, 2011. http://www.palliativecare.org.au/Portals/46/PAL31612%20consensus%20 statement_newer%20style%203%20(2).pdf (accessed Oct 2012).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.